[ALKS] Alkermes plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 57.99 Change: 1.68 (2.98%)
Ext. hours: Change: 0 (0%)

chart ALKS

Refresh chart

Strongest Trends Summary For ALKS

ALKS is in the long-term up 172% in 15 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension a

Fundamental Ratios
Shares Outstanding EPS-1.31 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 5.08% Sales Growth - Q/Q-7.96% P/E-43.63
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-1.89% ROE-2.56% ROI-2.04%
Current Ratio8.79 Quick Ratio8.36 Long Term Debt/Equity0.39 Debt Ratio0.08
Gross Margin72.77% Operating Margin-15.17% Net Profit Margin-5.6% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities17.94 M Cash From Investing Activities-31.78 M Cash From Operating Activities-13.33 M Gross Profit120.95 M
Net Profit-46.11 M Operating Profit-52.52 M Total Assets1.91 B Total Current Assets1.02 B
Total Current Liabilities134.22 M Total Debt354.81 M Total Liabilities515.68 M Total Revenue151.37 M
Technical Data
High 52 week67.26 Low 52 week33 Last close34.34 Last change-0.03%
RSI34.49 Average true range1.63 Beta1.3 Volume502.8 K
Simple moving average 20 days-7.13% Simple moving average 50 days-13.72% Simple moving average 200 days-25.44%
Performance Data
Performance Week0.73% Performance Month-14.21% Performance Quart-23.43% Performance Half-24.97%
Performance Year-31.53% Performance Year-to-date-37.26% Volatility daily3.16% Volatility weekly7.06%
Volatility monthly14.47% Volatility yearly50.11% Relative Volume195.73% Average Volume806.49 K
New High New Low

News

2019-06-18 15:42:13 | Did You Manage To Avoid Alkermes's NASDAQ:ALKS Painful 56% Share Price Drop?

2019-06-18 08:06:55 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-15 08:07:34 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-13 10:26:02 | Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230

2019-06-13 08:06:46 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-12 07:00:00 | Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

2019-06-11 11:04:05 | Here’s What Hedge Funds Think About Alkermes Plc ALKS

2019-06-11 08:08:20 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-10 08:07:53 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-08 08:12:57 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-06 09:30:01 | CBM vs. ALKS: Which Stock Should Value Investors Buy Now?

2019-06-06 08:08:01 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-04 08:08:27 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-05-31 09:07:01 | Biogen Reports Interim Phase III Data on Diroximel Fumarate

2019-05-30 07:30:00 | New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis

2019-05-29 10:34:02 | Allergan's AGN Vraylar Gets FDA Nod for Bipolar Depression

2019-05-25 09:31:01 | Why Is Alkermes ALKS Down 21% Since Last Earnings Report?

2019-05-22 11:34:56 | Does Alkermes plc's NASDAQ:ALKS CEO Salary Compare Well With Others?

2019-05-22 07:00:00 | Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting

2019-05-16 09:30:01 | ALXN or ALKS: Which Is the Better Value Stock Right Now?

2019-05-14 16:01:00 | Alkermes to Present at the UBS Global Healthcare Conference

2019-05-13 07:00:00 | Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences

2019-05-07 08:05:51 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-04-30 08:06:48 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-04-26 16:27:03 | Edited Transcript of ALKS earnings conference call or presentation 25-Apr-19 12:30pm GMT

2019-04-26 15:58:00 | Alkermes Looks Ahead to Growth

2019-04-26 09:11:00 | Alkermes PLC ALKS Q1 2019 Earnings Call Transcript

2019-04-26 07:26:11 | Alkermes ALKS Reports Narrower-Than-Expected Loss in Q1

2019-04-25 15:47:00 | Biogen Looks to 23 Clinical Programs for Growth

2019-04-25 15:21:00 | Here's Why Shares of Alkermes Sank Today

2019-04-25 09:30:01 | GILD vs. ALKS: Which Stock Is the Better Value Option?

2019-04-25 07:58:40 | The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

2019-04-25 07:00:00 | Alkermes Plc Reports First Quarter 2019 Financial Results

2019-04-25 06:30:00 | Alkermes Plc to Host Earnings Call

2019-04-24 16:01:00 | Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing

2019-04-24 13:43:27 | Here’s What Hedge Funds Think About Alkermes Plc ALKS

2019-04-19 13:37:20 | Has Alkermes plc NASDAQ:ALKS Got Enough Cash?

2019-04-18 16:00:00 | Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results

2019-04-18 10:33:02 | Earnings Preview: Alkermes ALKS Q1 Earnings Expected to Decline

2019-04-11 07:48:23 | The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

2019-04-10 10:46:02 | Alkermes Reports Positive Data From Schizophrenia Study

2019-04-09 10:51:30 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-04-09 07:35:29 | Alkermes says long-acting drugs could help schizophrenics stay on medication longer

2019-04-09 07:00:00 | Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

2019-04-08 17:15:00 | Alkermes Announces Departure of Jim Robinson

2019-04-07 17:04:02 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

2019-04-03 07:00:00 | Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia

2019-04-02 11:55:56 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-04-01 12:38:52 | Drug companies that benefit from the war on opioid addiction

2019-04-01 07:00:00 | Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society